Xinlitai (002294.SZ): Application for listing of Taicaski monoclonal antibody injection has been accepted.

Zhtng Cijng APP News, Xnlti (002294.SZ) announced that the company and its subsidiary Xnlti (Szhu) Yoy Yuxin Gngs's independently developed Class 1 biopharmaceutical "Tikx dnkng zhsh y" has submitted a listing application to the National Medical Products Administration and has been accepted. The intended indications for application are: hypercholesterolemia and mixed dyslipidemia.